Skip to main
ACLX
ACLX logo

Arcellx (ACLX) Stock Forecast & Price Target

Arcellx (ACLX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 62%
Buy 31%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Arcellx Inc. has demonstrated strong growth potential, evidenced by Carvykti sales increasing by an average of 32% quarter-over-quarter over the past 12 quarters. The company is poised to capture a significant share of the BCMA CAR T market, projected to expand from approximately $2.2 billion in 2025 to around $11.5 billion by 2035, bolstered by promising clinical data and a favorable safety profile for its product, anito-cel. Additionally, a rise in the proportion of community physicians capable of administering CAR T therapies—from 29% to 47%—indicates an expanding market accessibility and support for Arcellx's innovative therapies.

Bears say

The financial outlook for Arcellx Inc. is hampered by conservative sales estimates for its lead product, anti-cel, which fall below consensus due to a projected decline in the overall CAR T market for multiple myeloma, with 2035 estimates of $11.5 billion compared to the consensus of $16.5 billion. Furthermore, there are significant risks surrounding the execution of its drug pipeline and ongoing concerns regarding drug pricing controls, exacerbated by volatile capital market conditions affecting biotechnology funding. Lastly, although there is a considerable patient population for CAR T therapies, logistical challenges in community settings are contributing to suboptimal adoption rates, which further complicates the commercial potential of Arcellx’s offerings.

Arcellx (ACLX) has been analyzed by 13 analysts, with a consensus rating of Buy. 62% of analysts recommend a Strong Buy, 31% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arcellx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arcellx (ACLX) Forecast

Analysts have given Arcellx (ACLX) a Buy based on their latest research and market trends.

According to 13 analysts, Arcellx (ACLX) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $114.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $114.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arcellx (ACLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.